


CLAIMS

What is claimed is:

1. Use of a compound represented by:



Formula (I),

in the manufacture of a medicament for treating a patient suffering from an advanced gastrointestinal stromal tumor, where the patient has a) a *KIT* exon 17 and/or a *KIT* exon 18 mutation and b) a *KIT* exon 11 mutation, wherein:

150mg of the compound is to be administered to the patient daily or twice daily, and where before the administration of the compound, the patient has progressed on or was intolerant to imatinib; and

wherein upon administration of the compound the patient achieves significantly more progression free survival time as determined by mRECIST1.1, and significantly more overall survival time, as compared to a patient with a *KIT* exon 17 and/or a *KIT* exon 18 mutation and a *KIT* exon 11 mutation suffering from an advanced gastrointestinal stromal tumor who has progressed on or was intolerant to imatinib and was then administered 50 mg sunitinib once daily.


2. The use of claim 1, where the patient has a) the *KIT* exon 17 and/or the *KIT* exon 18 mutation and b) the *KIT* exon 11 mutation in circulating tumor DNA.

3. The use of claim 1 or 2, wherein the patient being administered the compound does not have a *KIT* exon 9, or does not have a *KIT* exon 13 or 14 mutation in circulating tumor DNA.

4. The use of any one of claims 1-3, wherein the patient being administered the compound does not have a *KIT* exon 9, and does not have a *KIT* exon 13 or 14 mutation in circulating tumor DNA.

5. The use of any one of claims 1-4, wherein the patient being administered the compound has a progression free survival of at least about 14 months as compared to a progression free survival of about 1.5 months for the patient administered sunitinib.


6. The use of any one of claims 1-5, wherein 150 mg of the compound is to be administered once or twice daily for at least 40 days to the patient.
7. The use of any one of claims 1-6, wherein 150 mg of the compound is to be administered to the patient once daily.
8. Use of a compound represented by:



Formula (I),

in the manufacture of a medicament for treating a patient suffering from an advanced gastrointestinal stromal tumor who has a *KIT* exon 17 and/or a *KIT* exon 18 mutation, does not have *KIT* exon 13 and/or 14 mutation, and does not have a *KIT* exon 9 mutation, and where the patient has progressed on or was intolerant to imatinib, wherein: 150mg of the compound is to be administered to the patient daily or twice daily.

9. The use of claim 8, wherein the patient has the *KIT* exon 17 and/or a *KIT* exon 18 mutation, does not have the *KIT* exon 13 and/or 14 mutation, and does not have the *KIT* exon 9 mutation, in circulating tumor DNA.
10. The use of claim 8 or 9, wherein the patient's circulating tumor DNA also has a *KIT* exon 11 mutation.
11. The use of any one of claims 8-10, wherein 150 mg of the compound is to be administered to the patient daily.
12. Use of a compound represented by:




Formula (I),

in the manufacture of a medicament for treating a patient suffering from an advanced gastrointestinal stromal tumor where the patient has progressed on or was intolerant to imatinib, and the patient's circulating tumor DNA has a *KIT* exon 17 and/or a *KIT* exon 18 mutation and does not have a *KIT* exon 9 mutation, wherein:

150 mg of the compound is to be administered to the patient daily or twice daily.

13. The use of claim 12, wherein 150 mg of the compound is to be administered to the patient daily.

14. Use of a compound represented by:



Formula (I),

in the manufacture of a medicament for treating an advanced gastrointestinal stromal tumor where the patient has progressed on or was intolerant to imatinib in a patient in need thereof, wherein:

a patient having a circulating tumor DNA *KIT* exon 17 and/or a *KIT* exon 18 mutation and without one or more of a *KIT* exon 9, 13, and 14 mutation is to be selected to obtain a selected patient;

150mg of the compound is to be administered to the selected patient daily or twice daily;

or if the patient is not a selected patient, the patient is to be administered one or more different kinase inhibitors.

15. The use of claim 14, wherein if the patient is not a selected patient, the one or more different kinase inhibitors includes sunitinib.

16. The use of claim 14, wherein if the patient is not a selected patient, 50 mg of sunitinib is to be administered to the patient once daily.

17. The use of claim 15 or 16, wherein if the patient is not a selected patient and has further progressed at least after the sunitinib administration, 150 mg of the compound is to be further administered to the patient daily or twice daily.

18. The use of any one of claims 14-17, wherein the selected patient is to be administered 150 mg of the compound once daily.